Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 109, Issue 5, Pages djw272
Publisher
Oxford University Press (OUP)
Online
2016-10-22
DOI
10.1093/jnci/djw272
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Colon Cancer, Version 3.2014
- (2017) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- Prognostic Effect ofBRAFandKRASMutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab
- (2016) Julien Taieb et al. JAMA Oncology
- Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
- (2015) F. A. Sinicrope et al. CLINICAL CANCER RESEARCH
- Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
- (2015) Frank A. Sinicrope et al. GASTROENTEROLOGY
- Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers
- (2015) E.M.V. de Cuba et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients
- (2015) An Na Seo et al. TUMOR BIOLOGY
- HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
- (2015) S. M. Kavuri et al. Cancer Discovery
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
- (2014) H. Blons et al. ANNALS OF ONCOLOGY
- KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
- (2014) H. H. Yoon et al. CLINICAL CANCER RESEARCH
- Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
- (2014) Julien Taieb et al. LANCET ONCOLOGY
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial
- (2013) Shuji Ogino et al. JNCI-Journal of the National Cancer Institute
- Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
- (2013) Felipe De Sousa E Melo et al. NATURE MEDICINE
- Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
- (2012) Tomoya Yokota Anti-Cancer Agents in Medicinal Chemistry
- Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
- (2012) Y. Imamura et al. CLINICAL CANCER RESEARCH
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
- (2012) P. G. Gavin et al. CLINICAL CANCER RESEARCH
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer
- (2012) Daniel J. Sargent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma
- (2012) Frank Benedix et al. PATHOLOGY RESEARCH AND PRACTICE
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Prognostic Significance and Molecular Associations of Tumor Growth Pattern in Colorectal Cancer
- (2011) Teppei Morikawa et al. ANNALS OF SURGICAL ONCOLOGY
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
- (2011) S. Ogino et al. CLINICAL CANCER RESEARCH
- p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers
- (2011) Catherine E. Bond et al. INTERNATIONAL JOURNAL OF CANCER
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
- (2010) A. Fariña-Sarasqueta et al. ANNALS OF ONCOLOGY
- Role of the Serrated Pathway in Colorectal Cancer Pathogenesis
- (2010) Barbara Leggett et al. GASTROENTEROLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Distinct CpG island methylation profiles andBRAFmutation status in serrated and adenomatous colorectal polyps
- (2008) Yong Ho Kim et al. INTERNATIONAL JOURNAL OF CANCER
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now